Literature DB >> 7716848

Evaluation of erectile function in men with sickle cell disease.

A L Burnett1, R P Allen, C M Tempany, G J Dover, C B Brendler.   

Abstract

OBJECTIVES: To evaluate and characterize erectile manifestations associated with sickle cell disease using nocturnal penile tumescence testing with polysomnography (NPT/PSG) and magnetic resonance imaging (MRI) of the penis.
METHODS: Six variably potent men with sickle cell disease, of whom 5 reported a history of priapism, underwent comprehensive evaluations of erectile function. Evaluations involved a medical history and physical examination with completion of priapism and sexual function questionnaires, followed by NPT/PSG and MRI of the penis.
RESULTS: Many different erectile abnormalities were identified in this group using NPT/PSG, although nocturnal erection durations as well as detumescence times were uniformly prolonged. Various axial rigidity measurements were obtained, which correlated fairly well with individual reports of erectile function. MRI findings ranged from normal corporeal anatomy to corporeal destruction with intracorporeal fibrosis and hemosiderin deposition.
CONCLUSIONS: In sickle cell disease, the erectile dysfunction that commonly occurs may be markedly different among men with this disease and may not always be predicted on the basis of clinical history of priapism. Generally, clinical assessments of erectile function may be derived from clinical histories and physical examinations. NPT/PSG and MRI of the penis are in accord with these assessments, obviating their routine use, although they may be valuable management adjuncts in certain situations.

Entities:  

Mesh:

Year:  1995        PMID: 7716848     DOI: 10.1016/s0090-4295(99)80059-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

Review 1.  Stuttering priapism: insights into pathogenesis and management.

Authors:  Belinda F Morrison; Arthur L Burnett
Journal:  Curr Urol Rep       Date:  2012-08       Impact factor: 3.092

2.  Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling.

Authors:  Tiejuan Mi; Shahrzad Abbasi; Hong Zhang; Karen Uray; Janci L Chunn; Ling Wei Xia; Jose G Molina; Norman W Weisbrodt; Rodney E Kellems; Michael R Blackburn; Yang Xia
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

3.  Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism.

Authors:  Jiaming Wen; Xianzhen Jiang; Yingbo Dai; Yujin Zhang; Yuxin Tang; Hong Sun; Tiejuan Mi; Rodney E Kellems; Michael R Blackburn; Yang Xia
Journal:  J Sex Med       Date:  2010-09       Impact factor: 3.802

4.  Molecular analysis of erection regulatory factors in sickle cell disease associated priapism in the human penis.

Authors:  Gwen Lagoda; Sena F Sezen; Marcelo R Cabrini; Biljana Musicki; Arthur L Burnett
Journal:  J Urol       Date:  2012-10-08       Impact factor: 7.450

Review 5.  Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature.

Authors:  Da-Chao Zheng; Hai-Jun Yao; Ke Zhang; Ming-Xi Xu; Qi Chen; Yan-Bo Chen; Zhi-Kang Cai; Mu-Jun Lu; Zhong Wang
Journal:  Asian J Androl       Date:  2012-08-27       Impact factor: 3.285

6.  Prevalence of Priapism and Its Awareness amongst Male Homozygous Sickle Cell Patients in Lagos, Nigeria.

Authors:  Adewumi Adediran; Kikelomo Wright; Akinsegun Akinbami; Adedoyin Dosunmu; Olajumoke Oshinaike; Bodunrin Osikomaiya; Sarah Ajibola; Kamal Ismail; Ebele Uche; Olaitan Ojelabi
Journal:  Adv Urol       Date:  2013-07-15

7.  Differences in polysomnographic, nocturnal penile tumescence and penile doppler ultrasound findings in men with stuttering priapism and sleep-related painful erections.

Authors:  Mark Johnson; Venkata McNeillis; Julia Gutbier; Andy Eaton; Robert Royston; Thomas Johnson; Giovanni Chiriaco; Miles Walkden; David Ralph
Journal:  Int J Impot Res       Date:  2021-08-13       Impact factor: 2.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.